Journal article

MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose

Jeremy Booth, Vincent Caillet, Adam Briggs, Nicholas Hardcastle, Georgios Angelis, Dasantha Jayamanne, Meegan Shepherd, Alexander Podreka, Kathryn Szymura, Trang Nguyen Doan, Per Poulsen, Ricky O'Brien, Benjamin Harris, Carol Haddad, Thomas Eade, Paul Keall

Radiotherapy and Oncology | ELSEVIER IRELAND LTD | Published : 2021


BACKGROUND AND PURPOSE: The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions. METHODS AND MATERIALS: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder-guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PT..

View full abstract